Wednesday, 25 April 2012

Food And Drug Administration-Consumer Advocacy Group-Diabetes Drug-Novo Nordisk

Novo Nordisk rejects diabetes drug Victoza complaint

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk rejected a consumer advocacy group's complaint about its big-selling diabetes drug Victoza as groundless and said it did not expect U.S. regulators to take any action. Its shares initially dropped more than 2 percent in brisk trade on Friday after non-profit group Public Citizen asked the U.S. Food And Drug Administration (FDA) to withdraw approval of Victoza. Novo Nordisk, the world's biggest producer of insulin used to treat diabetes, was the most-traded stock on the Copenhagen bourse, with more than 350 million Danish crowns ($61. ... read more..

No comments:

Post a comment